4142-51-2Relevant articles and documents
Synthesis and anticancer potential of novel xanthone derivatives with 3,6-substituted chains
Liu, Chaomei,Zhang, Mei,Zhang, Zhenhuan,Zhang, Steven B.,Yang, Shanmin,Zhang, Amy,Yin, Liangjie,Swarts, Steven,Vidyasagar, Sadasivan,Zhang, Lurong,Okunieff, Paul
, p. 4263 - 4271 (2016/08/23)
In an effort to develop new drug candidates with enhanced anticancer activity, our team synthesized and assessed the cytotoxicity of a series of novel xanthone derivatives with two longer 3,6-disubstituted amine carbonyl methoxy side chains on either benzene ring in selected human cancer cell lines. An MTT assay revealed that a set of compounds with lower IC50values than the positive control, 5-FU, exhibited greater anticancer effects. The most potent derivative (XD8) exhibited anticancer activity in MDA-MB-231, PC-3, A549, AsPC-1, and HCT116 cells lines with IC50values of 8.06, 6.18, 4.59, 4.76, and 6.09?μM, respectively. Cell cycle analysis and apoptosis activation suggested that the mechanism of action of these derivatives includes cell cycle regulation and apoptosis induction.
Antioxidant xanthone derivatives induce cell cycle arrest and apoptosis and enhance cell death induced by cisplatin in NTUB1 cells associated with ROS
Cheng, Jen-Hao,Huang, A-Mei,Hour, Tzyh-Chyuan,Yang, Shyh-Chyun,Pu, Yeong-Shiau,Lin, Chun-Nan
, p. 1222 - 1231 (2011/04/22)
In an effort to develop novel antioxidant as anticancer agents, a series of xanthones were prepared. In vitro screening, the synthetic xanthones revealed significant inhibitory effects on xanthine oxidase and ABTS radical-cation scavenging activity. The selective compounds 2 and 8 induced an accumulation of NTUB1 cells in the G1 phase arrest and cellular apoptosis by the increase of ROS level. The combination of cisplatin and 2 significantly enhanced the cell death in NTUB1 cells. Compounds 2 and 8 did not show cytotoxic activity in selected concentrations against SV-HUC1 cells. The present results suggested that antioxidants 2 and 8 may be used as anticancer agent for enhancing the therapeutic efficacy of anticancer agents and to reduce their side effect.
Selective Dealkylation of Methoxyanthraquinones via Difluoro1,O9>boron Chelates: Synthesis of Hydroxymethoxyanthraquinones
Preston, Peter N.,Winwick, Thomas,Morley, John O.
, p. 1439 - 1441 (2007/10/02)
1,8-, 1,5- 1,2-, and 1,4-Dimethoxyanthraquinones have been treated with boron trifluoride-diethyl ether to give difluoro(anthraquinonato)boron chelates (1a-d) respectively. 1,4,5-Trimethoxyanthraquinone was similarly converted separately in benzene and toluene into the mono- (2) and bis-difluoroboron(3)-chelates respectively, and 2,2',4,4'-tetramethoxybenzophenone was converted by BF3*Et2O in toluene into the boron adduct (4).Treatment of these derivatives, (1a-d) and (2)-(4), with methanol gave the following uncomplexed derivatives in good yield respectively: 1-hydroxy-8-methoxyanthraquinone, 1-hydroxy-5-methoxyanthraquinone, 1-hydroxy-2-methoxyanthraquinone, 1-hydroxy-4-methoxyanthraquinone, 4-hydroxy-1,5-dimethoxyanthraquinone, 1,4-dihydroxy-5-methoxyanthraquinone, and 2-hydroxy-2',4,4'-trimethoxybenzophenone.
